Bacteriophage lysins as antibacterials

  title={Bacteriophage lysins as antibacterials},
  author={U. Sharma and V. Paul},
  journal={Critical Care},
We read the editorial entitled “Non-antibiotic treatments for bacterial diseases in an era of progressive antibiotic resistance” by Steven M. Opal published in Critical Care [1]. We want to congratulate the author for this timely editorial and appreciate the efforts to highlight various non-antibiotic-based approaches being pursued for treating drug-resistant bacteria. We fully agree that there is a need to consider these approaches as serious alternatives to conventional antibiotics. In the… Expand
4 Citations
Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria
The therapeutic potential of phages is discussed and challenges and recent developments are described. Expand
Possible Role for Bacteriophages in the Treatment of SARS-CoV-2 Infection
It is hypothesized that the Ganges river may play a therapeutic role in the treatment of COVID-19, because it is known to harbor a large number of bacteriophages, which are released into the river gradually by the melting permafrost. Expand
Restoration of sensitivity of a diverse set of drug‐resistant Staphylococcus clinical strains by bactericidal protein P128
The ability of P128 to re‐sensitize bacteria to SoC drugs suggests that combinations of P 128 and SoC antibiotics can potentially be developed to treat infections caused by drug‐resistant strains of staphylococci. Expand
Non-antibiotic antimicrobial interventions and antimicrobial stewardship in wound care.
In this narrative review, current and emerging non-antibiotic antimicrobial strategies will be considered and the need for antimicrobial stewardship in wound care will be explained. Expand


Bacteriophage endolysins as novel antimicrobials.
The modular structure of endolysins is reviewed, in which cell wall binding and catalytic functions are separated, as well as their mechanism of action, lytic activity and potential as antimicrobials. Expand
Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens.
  • V. Fischetti
  • Biology, Medicine
  • International journal of medical microbiology : IJMM
  • 2010
Lysins' specificity for the pathogen without disturbing the normal flora, the low chance of bacterial resistance, and their ability to kill colonizing pathogens on mucosal surfaces, a capacity previously unavailable, make them ideal anti-infectives in an age of mounting resistance. Expand
Art-175 Is a Highly Efficient Antibacterial against Multidrug-Resistant Strains and Persisters of Pseudomonas aeruginosa
Art-175 is a novel antibacterial that is well suited for a broad range of applications in hygiene and veterinary and human medicine, with a unique potential to target persister-driven chronic infections. Expand
Bacteriophage endolysins: applications for food safety.
This review summarizes and discusses recent developments regarding the use of endolysins for food safety, including the application of high-affinity endolysin-derived cell wall binding domains for rapid detection of pathogenic bacteria. Expand
Alternatives to antibiotics-a pipeline portfolio review.
This first wave of alternatives to antibiotics will probably best serve as adjunctive or preventive therapies, which suggests that conventional antibiotics are still needed. Expand
Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus–Induced Murine Bacteremia
Lysin CF-301 demonstrates activity on drug-resistant strains, has a low resistance profile, eradicates biofilms, and acts synergistically with antibiotics, and represents an attractive alternative to antibiotic monotherapies currently used to treat S. aureus bacteremia. Expand
Antibiofilm Activity and Synergistic Inhibition of Staphylococcus aureus Biofilms by Bactericidal Protein P128 in Combination with Antibiotics
In an in vitro mixed-biofilm model mimicking the wound infection environment, P128 was able to prevent biofilm formation by virtue of its anti-Staphylococcus activity and is an encouraging sign for the development of P128 for treatment of complicated S. aureus infections involving biofilms. Expand
Non-antibiotic treatments for bacterial diseases in an era of progressive antibiotic resistance
This work has suggested that antibiotics will continue to reliably treat some infections but will likely need adjuvant therapies or will need to be replaced for many bacterial infections in the future. Expand
LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammation
It is found that Lys GH15 did not induce resistance in MRSA or methicillin-sensitive S. aureus (MSSA) strains after repeated treatment, and LysGH15-specific antibodies did not affect the killing efficiency of LysGH 15 against MRSA in vitro or in vivo. Expand
Antibiofilm activity and synergistic inhibition of S. aureus biofilms by bactericidal protein P128 in combination with antibiotics
  • Antimicrob Agents Chemother
  • 2016